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Abstract
Invasive lobular breast cancer (ILC) accounts for 10–15% of all invasive breast carcinomas. It is generally ER positive (ER+) and
often associated with lobular carcinoma in situ (LCIS). Genome-wide association studies have identified more than 70 common
polymorphisms that predispose to breast cancer, but these studies included predominantly ductal (IDC) carcinomas. To
identify novel common polymorphisms that predispose to ILC and LCIS, we pooled data from 6,023 cases (5,622 ILC, 401 pure
LCIS) and 34,271 controls from 36 studies genotyped using the iCOGS chip. Six novel SNPs most strongly associated with ILC/
LCIS in the pooled analysis were genotyped in a further 516 lobular cases (482 ILC, 36 LCIS) and 1,467 controls. These analyses
identified a lobular-specific SNP at 7q34 (rs11977670, OR (95%CI) for ILC = 1.13 (1.09–1.18), P= 6.0610210; P-het for ILC vs IDC
ER+ tumors = 1.861024). Of the 75 known breast cancer polymorphisms that were genotyped, 56 were associated with ILC and
15 with LCIS at P,0.05. Two SNPs showed significantly stronger associations for ILC than LCIS (rs2981579/10q26/FGFR2, P-
het = 0.04 and rs889312/5q11/MAP3K1, P-het = 0.03); and two showed stronger associations for LCIS than ILC (rs6678914/1q32/
LGR6, P-het = 0.001 and rs1752911/6q14, P-het = 0.04). In addition, seven of the 75 known loci showed significant differences
between ER+ tumors with IDC and ILC histology, three of these showing stronger associations for ILC (rs11249433/1p11,
rs2981579/10q26/FGFR2 and rs10995190/10q21/ZNF365) and four associated only with IDC (5p12/rs10941679; rs2588809/
14q24/RAD51L1, rs6472903/8q21 and rs1550623/2q31/CDCA7). In conclusion, we have identified one novel lobular breast
cancer specific predisposition polymorphism at 7q34, and shown for the first time that common breast cancer polymorphisms
predispose to LCIS. We have shown that many of the ER+ breast cancer predisposition loci also predispose to ILC, although
there is some heterogeneity between ER+ lobular and ER+ IDC tumors. These data provide evidence for overlapping, but
distinct etiological pathways within ER+ breast cancer between morphological subtypes.
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Introduction
Invasive lobular breast cancer (ILC) accounts for 10–15% of all
invasive breast carcinomas and it has distinct etiological, clinical
and biological characteristics compared with the more common
invasive ductal/no special type carcinoma (IDC) [1]. Lobular
cancers show stronger associations with the use of hormone
replacement therapy (HRT) than IDC, [2] and its incidence
follows a similar temporal pattern as the use of combined HRT
[3]. ILC is characterized by E-cadherin loss and the malignant
cells therefore infiltrate the breast stroma in single files with little
associated stromal reaction. This makes it difficult to detect these
tumors by palpation or mammography, and they are often larger
at presentation than IDCs [4]. ILCs are generally of histological
grade 2 and estrogen receptor positive (ER+), with the exception of
the pleomorphic subgroup. They typically have a different pattern
of metastatic spread to IDCs, tending to infiltrate the peritoneum,
ovary and gastrointestinal system. There is some evidence that
they are less chemo-sensitive than IDC and that the 10-year
survival rate of women with ILC is lower than that of ER+ IDCs
[5,6].
ILC is often associated with lobular carcinoma in situ (LCIS), a
form of non-invasive breast cancer that is difficult to detect
clinically and typically found incidentally on biopsy. The increased
breast biopsy rate associated with screening mammography has
led to an increase in the diagnosis of LCIS. LCIS shares many of
the same genetic aberrations as ILC, suggesting that it is a
precursor lesion in an analogous manner to ductal carcinoma in
situ (DCIS) and IDC [7]. Women who have had LCIS are 2.4
times more likely to develop invasive breast cancer compared to
the general population, with an excess of ILC (23–80% of cases)
[8,9]. However only 50–70% of invasive cancers associated with
LCIS have lobular morphology [10, unpublished data from
GLACIER study]. The remaining cancers have a IDC or mixed
ductal-lobular appearance, but again are generally ER+ (95% of
IDC and mixed ductal-lobular cancers associated with LCIS in the
GLACIER study were ER+). Unlike DCIS, LCIS is also a risk
factor for developing invasive cancer in the contralateral breast
[8].
Genome-wide association studies (GWAS) in breast cancer
have identified loci that predispose to invasive breast cancer in
general, or specifically to ER+ or ER-negative disease [11–25].
However, no previous study has focused specifically on lobular
carcinomas. Only one common single nucleotide polymorphism
(SNP; rs11249433 at 1p11.2) has been shown to be more strongly
associated with lobular than ductal histology [26]. For the
remaining SNPs predisposing to ER+ tumors, it is unclear
whether the studies have lacked statistical power to identify
differential associations by histology, or whether associations tend
to be non-differential by morphology after accounting for ER
status.
The aim of this study was to identify new breast cancer
susceptibility loci specific to lobular carcinoma, and to evaluate the
heterogeneity of associations of known loci by morphology. This
involved pooling genotyping data from over 6,000 cases of lobular
carcinoma (ILC and/or LCIS) and over 34,000 controls
genotyped using the iCOGS chip, a custom SNP array that
comprises 211,155 SNPs enriched at predisposition loci for breast
and other cancers [24].
Results
In a phase I analysis, we evaluated risk associations between
SNPs on the iCOGS chip and risk of ILC and LCIS using 1,782
lobular cases (1,470 ILC with or without LCIS, 312 pure LCIS)
from GLACIER, a UK study of lobular breast cancer, and 4,755
UK controls from the Breast Cancer Association Consortium,
BCAC (Figure 1). There was little evidence for systematic inflation
of the test statistics, based on 37,544 uncorrelated SNPs that had
not been selected on the basis of breast cancer risk (l= 1.04;
Figure S1). Data were combined by meta-analysis with a further
4,241 cases (4,152 ILC, 89 LCIS) and 29,519 controls of European
ancestry, derived from 34 studies in BCAC, and previously typed
on the iCOGS chip (Tables S1 and S2). This resulted in a total of
6,023 cases (5,622 ILC, 401 LCIS) and 34,271 controls with data
on 199,961 iCOGS SNPs (after quality control exclusions and
with minor allele frequency (MAF) .0.01) included in the meta-
analysis.
Search for new lobular breast cancer predisposition loci
All SNPs reaching genome-wide significance (P,561028) in the
meta-analysis were correlated with one of the known breast cancer
predisposition loci. In order to identify new loci that predispose to
lobular carcinoma, we selected six uncorrelated SNPs
(rs11977670, rs2121783, rs2747652, rs3909680, rs9948182,
rs7034265) that were only weakly correlated (r2,0.25) with
known loci and that showed the best evidence of association (P
between 561028 and 561025) in the overall lobular case-control
analysis (ILC and LCIS). These SNPs were genotyped in a Phase
II including 516 cases (481 ILC, 35 LCIS) and 1,467 controls, all
from white European donors (Figure 1).
One of the six SNPs, rs11977670 at 7q34, reached genome-
wide significance in a pooled analysis of phase I and II ILC
cases and controls (OR = 1.13, 95%CI = 1.09–1.18,
P = 6.0610210, Table 1, Figure 2). rs11977670 showed a
similar association with LCIS (P-het for ILC vs LCIS = 0.198),
and a very weak or no association with IDC (OR = 1.02,
95%CI = 1.00–1.05, P = 0.070; P-het for ILC vs
IDC = 1.361025), indicating that this is a lobular specific
predisposition locus (Table 2). The risk allele appeared to act
in a dominant rather than additive manner: ORAG = 1.21,
95%CI = 1.14–1.30; ORAA = 1.27, 95%CI = 1.17–1.38; P for
departure from log-additivity = 0.009; Table S3. rs11977670
was not significantly associated with age at onset of ILC
(Ptrend = 0.16) and risk alleles were not significantly over-
represented in cases with a positive family history (FH)
(P = 0.90, FH+ vs FH2). None of the other 5 SNPs genotyped
Author Summary
Invasive lobular breast cancer (ILC) accounts for 10–15% of
invasive breast cancer and is generally ER positive (ER+). To
date, none of the genome-wide association studies that
have identified loci that predispose to breast cancer in
general or to ER+ or ER-negative breast cancer have
focused on lobular breast cancer. In this lobular breast
cancer study we identified a new variant that appears to
be specific to this morphological subtype. We also
ascertained which of the known variants predisposes
specifically to lobular breast cancer and show for the first
time that some of these loci are also associated with
lobular carcinoma in situ, a non-obligate precursor of
breast cancer and also a risk factor for contralateral breast
cancer. Our study shows that the genetic pathways of
invasive lobular cancer and ER+ ductal carcinoma mostly
overlap, but there are important differences that are likely
to provide insights into the biology of lobular breast
tumors.
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were associated with lobular breast cancer at a genome-wide
significance level, with the strongest association being for
rs2121783 at 3p13 (OR = 1.11, 95%CI = 1.07–1.15,
P = 4.561027; Table S4).
rs11977670 at 7q34 (position:139942304, GRCh Build 37) is
intergenic, 65 kb from the nearest gene, JHDM1D, a histone
demethylase and 500 kb from BRAF, a gene frequently mutated in
melanoma. It is also in close proximity to a predicted novel U1
spliceosomal RNA that contains two U1 specific promoter motifs
(Figure S2). ENCODE data on normal human mammary epithelial
cells (HMEC), and breast carcinoma (MCF-7), were used to
establish chromatin states in the region and showed that rs11977670
lies in region marked by H3K27 acetylation, Figure S3.
Using expression data from the Cancer Genome Atlas Network
(TCGA database) [27], we assessed expression of the nine genes
within 0.5 Mb of rs11977670 by breast cancer subtype (ER+ ILC,
40 cases; ER+ IDC, 341 cases; and ER-negative IDC, 108 cases;
Figure S4). Three genes showed differential expression in ER+
ILC compared to ER+ IDC (BRAF, P= 0.006; NDUFB2, P= 0.02,
SLC37A3, P= 0.05), however none reached statistical significance
when correcting for multiple testing. Another two genes, JHDM1D
and ADCK2, showed a difference in expression between ER-
negative and ER+ cancers, but this was not lobular-specific. To
further investigate which genes may be influenced by SNPs tagged
by rs11977670, germline genotype data for rs13225058 (A/G), a
surrogate for rs11977670 (G/A) (r2 = 0.79) was taken from the
TCGA database (SNP6.0 Affymetrix array) and compared to
expression of these genes, correcting for copy number variation, in
335 ER+ primary breast cancers where both genotype and
expression data was available. A significant difference, after
correcting for multiple testing, was found in expression between
the AA and GG genotype for two genes JHDM1D (P= 0.0005)
and SLC37A3 (P= 0.004), Figure S5a. Confining the analysis to
the 36 ILC cases with data in TCGA showed no significant
genotype specific expression due small numbers although there
was the suggestion of a trend towards overexpression with the GG
genotype (2 cases), Figure S5b. 48 of the cases also had expression
data on adjacent normal breast tissue, but due to the small
numbers no significant genotype specific expression changes were
detected, Figure S6. There was no evidence of copy number
variation around rs11977670 and no evidence of an excess of
somatic mutations in JHDM1D, SLC37A3 or BRAF in ILC.
Figure 1. Lobular cancer study design.
doi:10.1371/journal.pgen.1004285.g001
Genetic Predisposition to Lobular Breast Cancer
PLOS Genetics | www.plosgenetics.org 5 April 2014 | Volume 10 | Issue 4 | e1004285
Assessment of the 75 known breast cancer susceptibility
loci for association with ILC and LCIS
Most (56 of 75) known common breast cancer susceptibility loci
were associated with ILC at P,0.05 with the effect in the same
direction as previously reported (Table S5), and 13 of these reached
genome-wide significance (P,561028, Table 3). The strongest
associations were with SNPs close to FGFR2 (rs2981579, OR = 1.38,
P= 5.1610252), TOX3 (rs3803662, OR = 1.33, P= 1.1610235), at
1p11.2 (rs11249433, OR = 1.25, P= 2.7610225) and 11q13.3
(rs554219, OR = 1.33, P= 1.6610222). All 13 loci had previously
been shown to be associated with ER+ breast cancer and one locus,
rs11249433 (1p11.2), with lobular histology in subgroup analysis. Of
the remaining 19 SNPs with P$0.05, 18 had ORs in the same
direction as previously reported for overall breast cancer (Sign test
P= 0.0001), suggesting that these SNPs are also likely to predispose to
LCIS. Only one of the seven ER-negative specific loci on the
iCOGS array showed a significant association with ILC
(rs12710696, P= 0.037). In case-only analyses, no SNP showed an
association with family history of breast cancer or young age at onset
of ILC.
For the 75 known breast cancer susceptibility loci, case-control
analysis for the 401 cases of pure LCIS (without invasion) and
24,045 controls, revealed 15 out of 75 SNPs associated with LCIS
at P,0.05 (Table 3). The strongest associations were for rs865686
(9q31.2, P= 2.261025); rs3803662 (TOX3, P= 1.261024),
c11_pos69088342/rs75915166 (11q13.3, P= 7.861024) and
rs1243482 (MLLT10, 10p12.31, P= 7.861024) that is partially
correlated (r2 = 0.69) with rs7072776, a recently identified ER+
breast cancer predisposition locus that showed a weaker
association with LCIS (OR = 1.17, 95%CI = 1.00–1.36,
P= 0.05; Table S5). Forty-seven of the remaining 60 SNPs at
P.0.05 had ORs in the same direction as for ILC. This is greater
than one would expect by chance (Sign Test P= 1.261025)
suggesting many of these SNPs predispose to LCIS, but the study
did not have enough power to detect these associations with the
small sample size.
A global test in case-only analysis (ILC vs LCIS) indicated no
significant differences in associations of the 75 SNPs between
LCIS and ILC (likelihood ratio test (75 df) = 0.438). However,
individual SNP analyses suggested some differences. Two loci
showed stronger associations with ILC than pure LCIS:
rs2981579, FGFR2 (P-het = 0.02); and rs889312, 5q11.2 (P-
het = 0.03). Case-only analysis also suggested that two ER-negative
specific SNPs [23,25] were more strongly associated with LCIS
than ILC: rs6678914, 1q32.1 (P-het = 0.0007) and rs17529111,
6q14.1 (P-het = 0.04) Table 3. The remaining SNPs showed no
significant heterogeneity between ILC and LCIS.
Assessment of the 75 known susceptibility SNPs for
differential effects on ILC and IDC
In order to identify lobular specific SNPs, we performed a case-
only analysis of 3,201 ER+ ILC cases and 15,024 ER+ IDC cases
from BCAC. Analysis was confined to ER+ cases since 94% of
ILC cases were ER+ (compared to 78% of IDC in BCAC). A
global test indicated significant differences in SNP associations
between ILC and IDC (likelihood ratio test (75 df) P = 5.961026).
The SNP showing the largest difference between ILC and IDC
was rs11249433 at chr 1p11.2 (P-het = 2.761028; Table 4), a SNP
previously associated with lobular histology. At P,0.05, a further
two loci were associated more strongly with ILC than IDC:
rs2981579, FGFR2 (P-het = 5.361023) and rs10995190, 10q21.2
(P-het = 0.002). This analysis also identified four IDC-specific
SNPs at P,0.05: rs10941679, 5p12 (P-het = 1.561024);
rs2588809, RAD51L1 (P-het = 0.001); rs6472903, 8q21.11 (P-
het = 0.004); rs1550623, CDCA7 (P-het = 0.031) Table S6.
Assessment of the 75 known susceptibility SNPs for
effects on mixed ILC-IDC cancer predisposition
Case-control analysis of 690 mixed ductal–lobular carcinomas
revealed 25 loci that showed an association with these mixed cancers
at P,0.05. The top hits were at FGFR2 (rs2981579, OR = 1.37,
P= 1.661027), rs941764 (CCDC88C, OR = 1.25, P= 3.661024) and
rs10995190 (ZNF365, OR = 0.74, P= 3.961024). The case-only
analysis above showed that two of these SNPs are more strongly
associated with ILC than IDC (rs2981579, rs10995190). rs941764
showed no association with ILC and only weak association with ER+
IDC, Table S6.
Discussion
Our analyses of a total of 6,539 lobular cancers (including
436 cases of pure LCIS) and 35,710 controls has identified for
the first time a lobular-specific SNP, rs11977670 (JHDM1D;
OR = 1.13 P = 4.2610210, that showed little evidence of
association with IDC (P = 0.07) or DCIS (P = 0.23). Identifica-
tion of the target of this association will require fine mapping
of the region, followed by functional assays to determine which
gene(s) the key SNPs regulate. The preliminary in silico
functional analysis suggests that SNPs in this region may be
influencing expression of JHDM1D (a histone demethylase)
and SLC37A3 (a sugar-phosphate exchanger). For JHDM1D
this appears to be a recessive effect, in contrast to the
susceptibility data, which suggests a dominant effect. There
are little data on the role of these genes in cancer. There is
some evidence that increased expression of JHDM1D can
Table 1. rs11977670, chromosome 7:139942304 G.A, and association ILC in populations of European ancestry.
Study/Consortia N Studies Cases Controls MAF OR (95% CI)* P
Phase I
GLACIER 1 1,470 4,755 0.437 1.16 (1.07, 1.26) 6.161024
BCAC 34 4,150 29,488 0.429 1.10 (1.05, 1.16) 4.061025
Combined 35 5,620 34,243 0.430 1.12 (1.07, 1.16) 1.461027
Phase II
UK PHASE II 1 479 1,452 0.426 1.38 (1.19, 1.60) 2.961025
Phase I+II 36 6,099 5,695 0.430 1.13 (1.09, 1.18) 6.0610210
* per allele.
doi:10.1371/journal.pgen.1004285.t001
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suppress tumor growth by regulating angiogenesis [28] and
decreased expression promotes invasiveness, which is contrary
to what one would expect from the risk data [29]. This
inconsistency does shed some doubt on these results and
further analysis of the region is required before any firm
conclusion can be made. Studies of syndecan-1-deficient breast
cancer cells, which show increased cell motility and invasive-
ness, demonstrate decreased expression of both JHDM1D and
E-cadherin [29], suggesting the two genes may interact.
Somatic mutations in CDH1 (E-Cadherin) are frequent in
ILC and rare germline frameshift mutations in CDH1 have
been described in ILC, particularly in families with hereditary
diffuse gastric cancer (HDGC), but also in cases of familial ILC
with no HDGC [30,31]. However, none of the 56 SNPs in
CDH1 that were typed on the iCOGS chip showed any
association with lobular cancer at P,0.05.
It should also be noted that this study is not a true genome wide
association study for lobular breast cancer as the SNPs on the
iCOGS chips were chosen on the basis of some prior evidence of
association with breast cancer as a whole. Although ILC would
have been a small proportion of the samples in the discovery sets
for these SNPs it is possible that other lobular specific loci exist
that have not been included on the iCOGS chip. This is
particularly true for LCIS, which would only have been included
in the discovery set as a parallel phenotype when associated with
invasive disease.
Figure 2. Forest plot for rs11977670.
doi:10.1371/journal.pgen.1004285.g002
Genetic Predisposition to Lobular Breast Cancer
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75 of the known common breast cancer susceptibility loci were
assessed for association with ILC and LCIS. As cases of ILC were
included in the discovery sets that generated these susceptibility
loci and lobular breast cancer is generally ER+ (94% of the ILC
cases in this study were ER+) with the majority of ILCs classified
as luminal tumors [32], it is not surprising that the majority of
SNPs that we found to be associated with ILC were known to also
predispose to ER+ breast cancer. However, some loci were only
associated with ER+ IDC and not with ILC, particularly
rs10941679 at 5p12, previously shown to predispose more strongly
to ER-positive, lower-grade cancers [33], P-het = 2.761028.
Others showed a much stronger association with ILC than IDC,
particularly rs11249433 at 1p11.2, as previously described [26].
These data suggest specific etiological pathways for the develop-
ment of different histological subtypes of breast cancer, in addition
to common pathways that predispose to multiple tumor subtypes.
Despite the small number of pure LCIS cases without invasive
disease, our analyses have shown for the first time that many of the
SNPs that predispose to ILC also predispose to LCIS. Although
only 15 of the known breast cancer SNPs were associated with
LCIS risk at P,0.05, 47 of the remaining 60 SNPs at P.0.05 had
ORs in the same direction as for ILC (Sign Test P= 1.261025)
suggesting that many more SNPs are likely to be associated with
pure LCIS but did not reach statistical significance individually
because of the relatively few LCIS cases without associated ILC in
our sample set. This is not unexpected if LCIS is an intermediate
phenotype for ILC. However, a small number of SNPs had
differential effects on LCIS or ILC risk. Specifically, rs6678914 at
1q32.1 (LGR6), known to be an ER-negative specific SNP [25],
that appeared to be associated with LCIS but not ILC (P-
het = 0.0007), and rs17529111 at 6q14 preferentially associated
with ER-negative tumors [23] that had a stronger association with
LCIS than ILC (P-het = 0.04). We also identified SNPs in FGFR2
and at 5q11.2 (MAP3K1) that appear only to predispose to ILC,
but have little effect on LCIS suggesting that SNPs affect different
parts of the lobular carcinoma pathway. These findings are
surprising and as based on small numbers need confirmation in
future studies.
Some of the SNPs associated with both ILC and LCIS showed a
stronger effect size in LCIS compared to ILC (for example SNPs at
TOX3, 9q31.2, 11q13.3, ZNF365 and MLLT10). It is possible that
the SNPs that showed an association with both LCIS and ILC
predispose to the development of LCIS rather than ILC, and that
the effect size is smaller in ILC as not all cases of LCIS will become
invasive cancer. SNPs that predispose strongly to LCIS were also
associated with ER+ IDCs but again with stronger effect sizes in
LCIS, consistent with the fact that 30–40% of invasive tumors
associated with LCIS will not be ILC but will be IDC, mixed
ductal-lobular or other morphology.
One SNP, rs1243182 (MLLT10), that showed a strong
association with LCIS (LCIS: P= 7.861024, OR = 1.29; ILC:
P= 6.161029,OR = 1.14; ILC+LCIS: P= 3610210,OR = 1.15,
IDC: P= 1.461025,OR = 1.07, is partially correlated (r2 = 0.69)
with rs7072776, a recently identified ER+ breast cancer predis-
position locus, which showed no association with LCIS in this
study. It is also strongly correlated with rs1243180 (r2 = 0.80), an
ovarian cancer predisposition variant [34] and rs11012732
(r2 = 0.57), which predisposes to meningioma [35]. The ovarian
SNP, rs1243180, also showed a strong association with lobular
cancer (ILC+LCIS: P= 5.54610210; OR = 1.13). Conditional
analysis confirmed that this was not independent of rs1243182.
rs11012732 was not genotyped on the iCOGS chip. The increased
risk of ovarian carcinoma after breast cancer is well documented in
epidemiological studies [36]. Of note, there are also reports
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suggesting an association between breast cancer and meningioma
[37].
In conclusion, we have identified a novel lobular-specific
predisposition SNP at 7q34 close to JHDM1D that does not
appear to be associated with IDC. Most known breast cancer
predisposition SNPs also predispose to ILC, with some differential
effects between ILC and IDC. In addition, many SNPs
predisposing to invasive cancer are also likely to increase the risk
for LCIS. Overall, our analyses show that genetic predisposition to
IDC and lobular lesions (both ILC and LCIS) overlap to a large
extent, but there are important differences that are likely to
provide insights into the biology of lobular breast tumors.
Methods
Ethics statement
All studies were performed with ethical committee approval,
Table S7, and subjects participated in the studies after providing
informed consent.
Study populations
Phase I. Cases and controls came from 34 studies forming
part of the Breast Cancer Association Consortium (BCAC)
included in the COGS Project [13] (Table S1), and GLACIER
(A study to investigate the Genetics of LobulAr Carcinoma In
situ in EuRope MREC 06/Q1702/64), a UK case-only study
of lobular breast cancer. BCAC studies recruited all types of
breast cancer. Pathological information in BCAC was collected
by the studies individually but combined and checked through
standardized data control in a central database. A total of
4,152 ILC and 89 LCIS cases were identified by the central
BCAC pathology database (see Table S2 for number of cases
by study).
The GLACIER study recruited patients from participating
centers throughout the UK with the aim of identifying
predisposition genes for LCIS and/or ILC. Any patients aged
60 or less at the time of diagnosis, with a current or past history of
LCIS (with or without invasive disease of any histological
subtype) were eligible. A total of 2,539 cases were recruited:
2,167 were identified from local pathology reports in 97 UK
hospitals, 346 cases were identified through the British Breast
Cancer Study (BBCS) using UK Cancer Registry data and 26
cases from the Royal Marsden Breast Tissue Bank. Cryptic
relatedness analysis showed no evidence of overlap between these
samples and the BCAC samples. All these cases were genotyped
with the iCOGS chip and compared to 5,000 UK controls
selected from four UK studies participating in BCAC and already
typed on the iCOGS chip. Controls were randomly selected prior
to analysis so that each of these UK studies, including
GLACIER, had a case:control ratio of at least 1:2 (Table S8).
These controls were excluded from case-control comparisons
with BCAC cases from the originating study. This report includes
only cases of pure LCIS or ILC with or without LCIS. Cases of
LCIS with IDC or mixed lobular and ductal carcinoma in
GLACIER were excluded in order to perform meta-analyses with
the BCAC studies which do not have information on the presence
or absence of LCIS associated with an invasive cancer. After
excluding individuals based on genotyping quality (see Genotyp-
ing and Analysis) and non-European ancestry, data for the
GLACIER study available for analyses included 1,782 cases
(1,470 ILC (with or without LCIS), 312 pure LCIS) and 4,755
controls.
Phase II. A further 516 cases (481 ILC, 35 LCIS) and 1,465
controls were analyzed as part of Phase II. Controls were
recruited through the GLACIER study, but were not genotyped
in Phase I on the iCOGS chip to reduce costs, and were all
white West European. Cases came from the following studies:
232 cases from GLACIER, 176 from BBCS, 71 from
DietCompLyf [38], 39 from King’s Health Partners Cancer
Biobank (KHP-CB). All cases were white West European, apart
from the 39 samples from the KHP-CB where there were no
associated ethnicity data. For studies that had also participated
in Phase I, we selected samples so there was no overlap with the
samples in Phase I.
Genotyping and analysis
Phase I. After DNA extraction from peripheral blood,
GLACIER samples were genotyped on the iCOGS custom
Illumina iSelect, which contains 211,155 SNPs, at King’s College,
London. The remaining cases and controls were genotyped as part
of the COGS project described in detail elsewhere [13]. The
GLACIER cases were analyzed using the same QC criteria as the
COGS project. Briefly, genotypes were called using Illumina’s
proprietary GenCall algorithm and 10,000 SNPs were manually
inspected to verify the algorithm calling. Individuals were excluded
if genotypically not female, had overall call rate ,95% or were
ethnic outliers (248 cases) as identified by multi-dimensional
scaling, combining the genotyping data with the three Hapmap2
populations. SNPs with a Gencall rate of ,0.25, call rate ,95%
(call rate ,99% if MAF ,0.1) and HWE,1027 or evidence of
poor clustering on inspection of cluster plots were excluded. All
SNPs with MAF ,0.01 were excluded for this analysis. A cryptic
relatedness analysis of the whole dataset was performed using
46,918 uncorrelated SNPs and there was no evidence of any
duplicates.
For GLACIER cases and controls, principal component
analysis (PCA) was carried out on a subset of 46,918 uncorrelated
SNPs and used to exclude individuals or groups distinct from the
main cluster using the first five principal components (PCs), Figure
S7. Following removal of outliers (166 cases and 245 controls), the
PCA was repeated and the first five PCs included as covariates in
the analysis. The adequacy of the case-control matching was
evaluated using quantile-quantile plots of test statistics and the
inflation factor (l) calculated using only uncorrelated SNPs that
were not selected by BCAC and were not within one of the four
common fine-mapping regions, to minimize selection for SNPs
associated with breast cancer, Figure S1. As the majority of the
SNPs on the iCOGS array were selected from GWAS of breast,
ovarian and prostate cancer the SNPs selected for this analysis
were taken from the set of SNPs selected by the prostate
consortium, with the assumption that these SNPs were more
likely to be representative of common SNPs in terms of population
structure in our study than those selected by the breast or ovarian
consortia.
For each SNP, we estimated a per-allele log-odds ratio (OR) and
standard error by logistic regression, including the 5 PCs as
covariates, using PLINK v1.07 (http://pngu.mgh.harvard.edu/
purcell/plink/).
Genotyping and analysis of BCAC studies is described in detail
elsewhere [24], in brief data were analyzed using the Genotype
Library and Utilities (GLU) package to estimate per-allele ORs
and standard errors for each SNP using unconditional logistic
regression. All analyses were performed in subjects of European
ancestry (determined by PC analyses) and adjusted for study and
seven principal components.
Case-control odds ratio (OR) for ILC or LCIS cases vs controls
from BCAC and GLACIER were combined using inverse
variance-weighted fixed-effects meta-analysis, as implemented in
Genetic Predisposition to Lobular Breast Cancer
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METAL [39]. Case-only analyses were also carried out to
compare genotype frequencies for ILC vs LCIS (GLACIER and
BCAC) and ILC vs IDC (BCAC studies only), and were used as a
test for heterogeneity of ORs by tumor subtype. Any study without
data on both histological subtypes was dropped from the case-only
analysis.
Phase II. SNPs showing the strongest evidence for association
with lobular tumors (P,561025) in the meta-analysis (after
excluding previously reported loci) were genotyped at LGC
Genomics (formerly KBiosciences) in Phase II samples. Duplicate
samples genotyped on the iCOGS chip were included to assess the
concordance of the two genotyping methods. Cluster plots for
rs11977670 are shown in Figure S8.
A pooled analysis of ILC including Phase I (GLACIER and
BCAC) and Phase II data was performed. Data were analyzed
using STATA v.12 to estimate per-allele ORs and standard
errors for each SNP using unconditional logistic regression.
Differences in the strength of the associations with ILC, IDC
and LCIS were assessed using case-only analyses. A sign test was
used to test whether the number of SNPs showing associations in
the same direction in two different subtypes (i.e. LCIS vs ILC,
and IDC vs ILC) was significantly grater than expected by
chance. A likelihood ratio test was used as a global test of the
null hypothesis of no differences between subtypes for any of the
ORs of the 75 known loci evaluated. Stratum-specific estimates
of per-allele OR by categories of age and family history of
disease were obtained from logistic regression models and
differences in ORs across strata were tested using an interaction
term.
Bioinformatics
In order to establish the SNP’s functional role, a window of
10 kb both up and downstream was formed around the marker
and pairwise r2 values calculated using 1000 genome CEU
population data. Three SNPs were identified as being in LD (r2.
0.5) with rs11977670 and were compared to next generation
sequence technologies to elucidate the overlap between chroma-
tin states (ENCODE Project). Two cell lines, normal human
mammary epithelial (HMEC), and breast carcinoma (MCF-7),
were used to establish these chromatin states, i.e. active or
engaged enhancers (H3K27ac), nucleosome-depleted regions
(DNase I and FAIRE), and RNA polymerase linked regions
(Pol II). Expression data from the Cancer Genome Atlas Network
for each gene within a 1 Mb window of rs11977670 was analyzed
looking for differential expression in each breast cancer subtype
(ER+ ILC, 40 cases; ER+ IDC, 341 cases; and ER-negative IDC,
108 cases). Allele data for surrogate SNP rs13225058 was
obtained for all ER+ cases from TCGA. These 335 cases were
used to produce genotype specific gene expression data in R.
Differences in gene expression between the three genotypes were
tested for using one-way-anova, verified by t-test and visually by
boxplot. Linear regression was performed across all three
genotypes using copy number variation as a co-variate. Level 3
copy number variation data (hg19 build) was obtained from the
TCGA data portal.
Supporting Information
Figure S1 Quantile-quantile plot for GLACIER. A: QQ plot based
on the 37544 uncorrelated SNPs not selected on the basis of breast
cancer risk (l= 1.04). B:QQ plot for all SNPs in dataset (l= 1.09).
(PPTX)
Figure S2 LD block containing rs1197790.
(PPTX)
Figure S3 rs1197790 falls in a high H3K27ac region using
ENCODE data from normal human mammary epithelial
(HMEC), and breast carcinoma (MCF-7) cell lines to establish
chromatin states in the region.
(PPTX)
Figure S4 Gene expression data taken from TCGA for genes in
a 1 Mb window of rs11977670. Three genes showed differential
expression in ER+ ILC compared to ER+ IDC (BRAF, P= 0.006;
NDUFB2, P= 0.02, SLC37A3, P= 0.05).
(PPTX)
Figure S5 a: Genotype specific gene expression In ER+ Breast
Cancers. Gene expression and genotype data was taken from
TCGA and compared using a surrogate for rs11977670,
rs13225058 (r2 = 0.79) for 335 ER+ cancers. A significant
difference between the AA and GG genotype was only found for
two genes, JHDM1D and SLC37A3. b: Genotype specific gene
expression in 36 Invasive Lobular Cancers. Gene expression and
genotype data was taken from TCGA and compared using a
surrogate for rs11977670, rs13225058 (r2 = 0.79).
(PPTX)
Figure S6 Genotype specific gene expression in 48 cases of
normal breast tissue associated with ER+ breast cancer. Gene
expression and genotype data was taken from TCGA and
compared using a surrogate for rs11977670, rs13225058
(r2 = 0.79) for 48 cases with normal breast tissue.
(PPTX)
Figure S7 Results of principal components analysis (PCA) –
GLACIER cohort. A: PCA with the 3 HapMap populations. B:
PCA after exclusion of outliers (414 cases and 245 controls).
(PPTX)
Figure S8 Cluster plots for rs11977670 is on chromosome 7
(139942304). A: Phase I – iCOGS Array – GLACIER (Illumina).
B: Phase I – iCOGS Array – BCAC (Illumina). C: Phase II-
KASPAR (LGC Genomics).
(PPTX)
Table S1 Participating studies from the BCAC.
(DOCX)
Table S2 Number of lobular breast cancer cases per study.
(DOCX)
Table S3 Genotype-specific odds ratios for rs11977670 and risk
of lobular-specific breast cancer (based on pooled analysis of phase
I and II).
(DOCX)
Table S4 Results for borderline SNPs not reaching GWS after
Phase II.
(XLSX)
Table S5 Pooled lobular analysis of known SNPs (BCAC and
GLACIER).
(XLSX)
Table S6 Lobular and ductal associations with breast cancer risk
in BCAC subjects (ER pos only).
(XLSX)
Table S7 Details of ethical approval boards for each study.
(DOCX)
Table S8 Lobular cases and controls from UK BCAC studies.
Controls from each of these studies were randomly selected to obtain a
control group for GLACIER cases in a 1:2 case to control ratio.
(DOCX)
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